Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Wednesday, while the Dow rose 0.18% to 44,319.31, the NASDAQ increased 0.62% to 20,545.29, and the S&P 500 climbed 0.31% to 6,245.11 [1] - Communication services shares increased by 1.1%, while consumer staples stocks dipped by 1% [1] Commodity News - Oil prices rose by 0.6% to $68.74, while gold prices fell by 0.1% to $3,315.70. Silver decreased by 0.4% to $36.610, and copper dropped by 3.8% to $5.4715 [5] European Market - European shares showed positive performance, with the eurozone's STOXX 600 rising 0.71%, Spain's IBEX 35 Index increasing by 1.07%, London's FTSE 100 gaining 0.13%, Germany's DAX 40 up by 1.32%, and France's CAC 40 rising by 1.40% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei gaining 0.33%, while Hong Kong's Hang Seng fell by 1.06%, China's Shanghai Composite declined by 0.13%, and India's BSE Sensex decreased by 0.21% [7] Company Developments - Calidi Biotherapeutics, Inc. saw its shares surge by 353% to $1.48 due to advancements in cancer treatment [9] - SU Group Holdings Limited's shares increased by 155% to $1.1609 after securing an HK$88.5 million hospital contract [9] - Evoke Pharma, Inc. shares rose by 171% to $7.20 following a notice of allowance for a U.S. patent application [9] - Bitmine Immersion Technologies, Inc. shares dropped by 47% to $59.22 after filing for a mixed shelf [9] - RxSight, Inc. shares fell by 42% to $7.39 after revising its 2025 revenue guidance downwards [9] - Vertical Aerospace Ltd. shares decreased by 31% to $4.77 after announcing a $60 million public offering at $5/share [9] Inventory Data - U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May, aligning with preliminary estimates [11] - U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, marking the largest gain since January [11]

Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “We’re pleased to report continued stro ...

Core Viewpoint - Evoke Pharma, Inc. announced the acceptance of a new abstract for presentation at Digestive Disease Week 2025, focusing on the incidence of tardive dyskinesia in patients treated with metoclopramide [1][3] Company Overview - Evoke Pharma is a specialty pharmaceutical company that develops treatments for gastrointestinal disorders, particularly known for GIMOTI, a nasal spray formulation of metoclopramide for diabetic gastroparesis [6][7] - GIMOTI is the only FDA-approved treatment for diabetic gastroparesis, addressing a significant need in the market [3][7] Research and Findings - The upcoming presentation will compare the incidence rates of tardive dyskinesia in patients receiving continuous versus intermittent oral metoclopramide treatment, utilizing real-world data from over 100 million U.S. patients [2][4] - The research aims to clarify the long-term safety profile of metoclopramide, particularly regarding tardive dyskinesia, to support informed prescribing decisions [3][4] Event Details - The abstract titled "Comparison of the Incidence of Tardive Dyskinesia in Patients Receiving Continuous vs Intermittent Oral Metoclopramide" will be presented by Pierantonio Russo, MD, during a session on gastroparesis and small intestinal dysmotility on May 5, 2025 [4] - The abstract will be accessible to attendees via the DDW ePosters site and mobile app starting May 4, 2025 [4] Industry Context - Digestive Disease Week (DDW) is a major international event for professionals in gastroenterology, showcasing advancements in GI research and medicine [8]

Financial Performance - Full-year revenue reached $10.2 million, a 97% year-over-year increase, exceeding the prior guidance of $10 million[8] - Q4 revenue was $3.3 million, a 24.6% increase from Q3 2024[8] - The company raised $14.3 million, ensuring Nasdaq compliance and providing a cash runway into Q1 2026[8] - Cash and cash equivalents as of December 31, 2024, were $13.6 million[47] Commercial Growth - The cumulative prescriber base grew by 46% year-over-year[8] - Fills grew by 72% year-over-year[8] - Prescriptions grew by 22% year-over-year[8] Market Position and Strategy - GIMOTI has a unique market advantage as the first and only FDA-approved nasal spray for gastroparesis[10] - The company's conversion rate in 2024 was 51% on average, with steady improvement seen over the year[20] Cost Savings - Total healthcare costs in the GIMOTI arm were $15,227 lower compared to oral metoclopramide[30] Sales and Marketing - Over 40,000 healthcare professionals were reached through email, with over 60% of targets reached via email and a ~16% email open rate[34]